- Home
- HCI vs AUPH Comparison
HCI vs AUPH Comparison
Compare HCI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCI | AUPH |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | HCI | AUPH |
|---|---|---|
| Price | $192.00 | $16.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $230.00 | $17.25 |
| AVG Volume (30 Days) | 150.5K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 32.29 | N/A |
| EPS | ★ 15.80 | 0.55 |
| Revenue | ★ $816,578,000.00 | $265,808,000.00 |
| Revenue This Year | $19.65 | $21.76 |
| Revenue Next Year | $9.97 | $16.45 |
| P/E Ratio | ★ $12.40 | $29.47 |
| Revenue Growth | 8.75 | ★ 20.62 |
| 52 Week Low | $106.89 | $6.55 |
| 52 Week High | $210.50 | $16.54 |
Technical Indicators
Market Signals| Indicator | HCI | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 63.25 |
| Support Level | $183.13 | $16.00 |
| Resistance Level | $196.87 | $16.54 |
| Average True Range (ATR) | 5.68 | 0.44 |
| MACD | 2.32 | -0.03 |
| Stochastic Oscillator | 91.68 | 83.01 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.